Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gain Therapeutics (GANX) EPS (Weighted Average and Diluted) (2020 - 2025)

Gain Therapeutics (GANX) has 6 years of EPS (Weighted Average and Diluted) data on record, last reported at -$0.15 in Q3 2025.

  • For Q3 2025, EPS (Weighted Average and Diluted) rose 11.76% year-over-year to -$0.15; the TTM value through Sep 2025 reached -$0.61, up 44.55%, while the annual FY2024 figure was -$0.89, 47.95% up from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.15 in Q3 2025 per GANX's latest filing, up from -$0.19 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$0.11 in Q4 2024 and bottomed at -$0.62 in Q2 2023.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.31, with a median of -$0.3 recorded in 2021.
  • Peak YoY movement for EPS (Weighted Average and Diluted): soared 66.04% in 2021, then crashed 122.22% in 2022.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.18 in 2021, then crashed by 122.22% to -$0.4 in 2022, then rose by 27.5% to -$0.29 in 2023, then soared by 62.07% to -$0.11 in 2024, then plummeted by 36.36% to -$0.15 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were -$0.15 in Q3 2025, -$0.19 in Q2 2025, and -$0.16 in Q1 2025.